[1] B. B. Aggarwal, A. Kumar and A. C. Bharti, “Anticancer Potential of Curcumin: Preclinical and Clinical Studies,” Anticancer Research, Vol. 23, No. 1A, 2003, pp. 363-398.
[2] O. P. Sharma, “Antioxidant Activity of Curcumin and Related Compounds,” Biochemical Pharmacology, Vol. 25, No. 15, 1976, pp. 1811-1812. doi:10.1016/0006-2952(76)90421-4
[3] A. J. Ruby, G. Kuttan, K. D. Babu, K. N. Rajasekharan and R. Kuttan, “Anti-Tumour and Antioxidant Activity of Natural Curcuminoids,” Cancer Letters, Vol. 94, No. 1, 1995, pp. 79-83. doi:10.1016/0304-3835(95)03827-J
[4] Y. Sugiyama, S. Kawakishi and T. Osawa, “Involvement of the Diketone Moiety in the Antioxidative Mechanism of Tetrahydrocurcumin,” Biochemical Pharmacology, Vol. 52, No. 4, 1996, pp. 519-525. doi:10.1016/0006-2952(96)00302-4
[5] R. C. Srimal and B. N. Dhawan, “Pharmacology of Diferuloyl Methane (Curcumin), a Non-Steroidal Anti-Inflammatory Agent,” Journal of Pharmacy and Pharmacology, Vol. 25, No. 6, 1973, pp. 447-452. doi:10.1111/j.2042-7158.1973.tb09131.x
[6] W. C. Jordan and C. R. Drew, “Curcumin––A Natural Herb with Anti-HIV Activity,” Journal of the National Medical Association, Vol. 88, No. 6, 1996, p. 333.
[7] G. B. Mahady, S. L. Pendland, G. Yun and Z. Z. Lu, “Turmeric (Curcuma longa) and Curcumin Inhibit the Growth of Helicobacterpylori, a Group 1 Carcinogen,” Anticancer Research, Vol. 22, No. 6C, 2002, pp. 4179-4181.
[8] M. K. Kim, G. J. Choi and H. S. Lee, “Fungicidal Property of Curcuma longa L. Rhizome-Derived Curcumin against Phytopathogenicfungi in a Greenhouse,” Journal of Agricultural and Food Chemistry, Vol. 51, No. 6, 2003, pp. 1578-1581. doi:10.1021/jf0210369
[9] R. C. Reddy, P. G. Vatsala, V. G. Keshamouni, G. Padmanaban and P. N. Rangarajan, “Curcumin for Malaria Therapy,” Biochemical and Biophysical Research Communications, Vol. 326, No. 2, 2005, pp. 472-474. doi:10.1016/j.bbrc.2004.11.051
[10] R. Kuttan, P. Bhanumathy, K. Nirmala and M. C. George, “Potentialanticancer Activity of Turmeric (Curcuma longa),” Cancer Letters, Vol. 29, No. 2, 1985, pp. 197-202. doi:10.1016/0304-3835(85)90159-4
[11] Y. Kiso, Y. Suzuki, N. Watanabe, Y. Oshima and H. Hikino, “Antihepatotoxic Principles of Curcuma longa Rhizomes,” Planta Medica, Vol. 49, No. 3, 1983, pp. 185-187. doi:10.1055/s-2007-969845
[12] N. Venkatesan, “Curcumin Attenuation of Acute Adriamycin Myocardialtoxicity in Rats,” British Journal of Pharmacology, Vol. 124, No. 3, 1998, pp. 425-427. doi:10.1038/sj.bjp.0701877
[13] N. Venkatesan, D. Punithavathi and V. Arumugam, “Curcuminprevents Adriamycin Nephrotoxicity in Rats,” British Journal of Pharmacology, Vol. 129, No. 2, 2000, pp. 231-234. doi:10.1038/sj.bjp.0703067
[14] R. Srivastava, M. Dikshit, R. C. Srimal and B. N. Dhawan, “Antithromboticeffect of Curcumin,” Thrombosis Research, Vol. 40, No. 3, 1985, pp. 413-417. doi:10.1016/0049-3848(85)90276-2
[15] M. Dikshit, L. Rastogi, R. Shukla and R. C. Srimal, “Prevention of Ischaemia-Induced Biochemical Changes by Curcumin & Quinidinein the Cat Heart,” Indian Journal of Medical Research, Vol. 101, 1995, pp. 31-35.
[16] C. Nirmala and R. Puvanakrishnan, “Protective Role of Curcuminagainst Isoproterenol Induced Myocardial Infarction in Rats,” Molecular and Cellular Biochemistry, Vol. 159, No. 2, 1996, pp. 85-93. doi:10.1007/BF00420910
[17] C. Nirmala and R. Puvanakrishnan, “Effect of Curcumin on Certainlysosomal Hydrolases in Isoproterenol-Induced Myocardial Infarctionin Rats,” Biochemical Pharmacol-ogy, Vol. 51, No. 1, 1996, pp. 47-51. doi:10.1016/0006-2952(95)02118-3
[18] M. Srinivasan, “Effect of Curcumin on Blood Sugar as Seen in Adiabetic Subject,” Indian Journal of Medical Science, Vol. 26, No. 4, 1972, pp. 269-270.
[19] P. S. Babu and K. Srinivasan, “Influence of Dietary Curcumin Andcholesterol on the Progression of Experimentally Induced Diabetesin Albino Rat,” Molecular and Cellular Biochemistry, Vol. 152, No. 1, 1995, pp. 13-21.
[20] P. S. Babu and K. Srinivasan, “Hypolipidemic Action of Curcumin, the Active Principle of Turmeric (Curcuma longa) in Streptozotocin Induced Diabetic Rats,” Molecular and Cellular Biochemistry, Vol. 166, No. 1-2, 1997, pp. 169-175. doi:10.1023/A:1006819605211
[21] N. Arun and N. Nalini, “Efficacy of Turmeric on Blood Sugar and Polyolpathway in Diabetic Albino Rats,” Plant Foods for Human Nutrition, Vol. 57, No. 1, 2002, pp. 41-52. doi:10.1023/A:1013106527829
[22] S. D. Deodhar, R. Sethi and R. C. Srimal, “Preliminary Study Onantirheumatic Activity of Curcumin (Diferuloyl Methane),” Indian Journal of Medical Research, Vol. 71, 1980, pp. 632-634.
[23] T. N. Shankar, N. V. Shantha, H. P. Ramesh, I. A. Murthy and V. S. Murthy, “Toxicity Studies on Turmeric (Curcuma longa): Acutetoxicity Studies in Rats, Guineapigs & Monkeys,” Indian Journal of Experimental Biology, Vol. 18, No. 1, 1980, pp. 73-75.
[24] S. Qureshi, A. H. Shah and A. M. Ageel, “Toxicity Studies on Alpiniagalanga and Curcuma longa,” Planta Medica, Vol. 58, No. 2, 1992, pp. 124-127. doi:10.1055/s-2006-961412
[25] C. D. Lao, M. F. Demierre and V. K. Sondak, “Targeting Events Inmelanoma Carcinogenesis for the Prevention of Melanoma,” Expert Review of Anticancer Therapy, Vol. 6, No. 11, 2006, pp. 1559-1568. doi:10.1586/14737140.6.11.1559
[26] C. D. Lao, M. T. Ruffin, D. Normolle, D. D. Heath, S. I. Murray, J. M. Bailey, M. E. Boggs, J. Crowell, C. L. Rock and D. E. Brenner, “Dose Escalation of a Curcuminoid Formulation,” BMC Complementary and Alternative Medicine, Vol. 6, 2006, p. 10. doi:10.1186/1472-6882-6-10
[27] A. L. Cheng, C. H. Hsu, J. K. Lin, M. M. Hsu, Y. F. Ho, T. S. Shen, J. Y. Ko, J. T. Lin, B. R. Lin, W. Ming-Shiang, H. S. Yu, S. H. Jee, G. S. Chen, T. M. Chen, C. A. Chen, M. K. Lai, Y. S. Pu, M. H. Pan, Y. J. Wang, C. C. Tsai and C. Y. Hsieh, “Phase I Clinical Trial of Curcumin, a Chemopreventive Agent, in Patients with High-Risk or Pre-Malignant Lesions,” Anticancer Research, Vol. 21, No. 4B, 2001, pp. 2895-900.
[28] G. Shoba, D. Joy, T. Joseph, M. Majeed, R. Rajendran and P. S. Srinivas, “Influence of Piperine on the Pharmacokinetics of Curcuminin Animals and Human Volunteers,” Planta Medica, Vol. 64, No. 4, 1998, pp. 353-356. doi:10.1055/s-2006-957450
[29] B. B. Aggarwal, C. Sundaram, N. Malani and H. Ichikawa, “Curcumin: The Indian Solid Gold,” Advances in Experimental Medicine and Biology, Vol. 595, 2007, pp. 1-75. doi:10.1007/978-0-387-46401-5_1
[30] C. H. Hsu and A. L. Cheng, “Clinical Studies with Curcumin,” Advances in Experimental Medicine and Biology, Vol. 595, 2007, pp. 471-480. doi:10.1007/978-0-387-46401-5_21
[31] R. Ravichandran, “Preparation and Characterisation of Curcumin Nanosuspension for Enhanced Solubility and Dissolution Velocity,” International Journal of Nano and Biomaterials, Vol. 3, No. 2, 2010, pp. 153-186. doi:10.1504/IJNBM.2010.037803
[32] A. B. Mohsen, A. A. Abdulaziz, A. A. Mohamed and M. A. Mohamed, “In Vivo Evaluation of Arteether Liposomes,” International Journal of Pharmaceutics, Vol. 175, No. 1, 1998, pp. 1-7. doi:10.1016/S0378-5173(98)00182-3
[33] K. Maiti, K. Mukherjee, A. Gantait, B. P. Saha and P. K. Mukherjee, “Curcumin-Phospholipid Complex: Preparation, Therapeutic Evaluation and Pharmacokinetic Study in Rats,” International Journal of Pharmaceutics, Vol. 330, No. 1-2, 2007, pp. 155-163. doi:10.1016/j.ijpharm.2006.09.025
[34] N. Hussain, V. Jaitley and A. T. Florence, “Recent Advances in the Understanding of Uptake of Microparticulates across the Gastrointestinal Lymphatics,” Advanced Drug Delivery Reviews, Vol. 50, No. 1-2, 2001, pp. 107-142. doi:10.1016/S0169-409X(01)00152-1
[35] D. D. Stuart and T. M. Allen, “A New Liposomal Formulation for Antisenseoligodeoxynucleotides with Small Size, High Incorporation Efficiency and Good Stability,” Biochimica et Biophysica Acta, Vol. 146, 2000, pp. 3219-3229.
[36] H. Yuan, J. Chen, Y. Z. Du, F. Q. Hu, S. Zeng and H. L. Zhao, “Studies on Oral Absorption of Stearic Acid SLN by a Novel Fluorometric Method,” Colloids and Surfaces B: Biointerfaces, Vol. 58, No. 2, 2007, pp. 157-164. doi:10.1016/j.colsurfb.2007.03.002
[37] R. N. Gursoy and S. Benita, “Self-Emulsifying Drug Delivery Systems (SEDDS) for Improved Oral Delivery of Lipophilic Drugs,” Biomedicine & Pharmacotherapy, Vol. 58, No. 3, 2004, pp. 173-182. doi:10.1016/j.biopha.2004.02.001
[38] S. J. Lim, M. K. Lee and C. K. Kim, “Altered Chemical and Biological Activities of All-Trans Retinoic Acid Incorporated in Solid Lipid Nanoparticle Powders,” Journal of Controlled Release, Vol. 100, No. 1, 2004, pp. 53-61. doi:10.1016/j.jconrel.2004.07.032
[39] T. Wisanu, L. Boonsom and L. Saisunee, “Flow Injection Analysis of Total Curcuminoids in Turmeric and Total Antioxidant Capacity Using 2,2Β0-Diphenyl-1-picrylhydrazyl Assay,” Food Chemistry, Vol. 112, 2009, pp. 494-499.
[40] S. Schmidt, D. Gonzalez and H. Derendorf, “Significance of Protein Binding in Pharmacokinetics and Pharmacodynamics,” Journal of Pharmaceutical Sciences, Vol. 99, No. 3, 2010, pp. 1107-1122. doi:10.1002/jps.21916
[41] S. M. Moghimi, A. C. Hunter and J. C. Murray, “Long-Circulating and Target-Specific Nanoparticles: Theory to Practice,” Pharmacological Reviews, Vol. 53, No. 2, 2001, pp. 283-318.
[42] E. Mastrobattista, G. A. Koning and G. Storm, “Immunoliposomes for the Targeted Delivery of Antitumor Drugs,” Advanced Drug Delivery Reviews, Vol. 40, No. 1-2, 1999, pp. 103-127. doi:10.1016/S0169-409X(99)00043-5
[43] K. Sou, S. Inenaga, S. Takeoka and E. Tsuchida, “Loading of Curcumin into Macrophages Using Lipid-Based Nanoparticles,” International Journal of Pharmaceutics, Vol. 352, No. 1-2, 2008, pp. 287-293. doi:10.1016/j.ijpharm.2007.10.033
[44] L. Li, B. Ahmed, K. Mehta and R. Kurzrock, “Liposomal Curcumin with and without Oxaliplatin: Effects on Cell Growth, Apoptosis, and Angiogenesis in Colorectal Cancer,” Molecular Cancer Therapeutics, Vol. 6, 2007, 1276-1282. doi:10.1158/1535-7163.MCT-06-0556
[45] Z. Ma, A. Shayeganpour, D. R. Brocks, A. Lavasanifar and J. Samuel, “Highperformance Liquid Chromatography Analysis of Curcumin in Rat Plasma: Application to Pharmacokinetics of Polymeric Micellar Formulation of Curcumin,” Biomedical Chromatography, Vol. 21, No. 5, 2007, pp. 546-552. doi:10.1002/bmc.795
[46] C. A. Mosley, D. C. Liotta and J. P. Snyder, “Highly Active Anticancer Curcumin Analogues,” Advances in Experimental Medicine and Biology, Vol. 595, 2007, pp. 77-103. doi:10.1007/978-0-387-46401-5_2
[47] A. Preetha, R. Banerjee and N. Huilgol, “Tensiometric Profiles and Their Modulation by Cholesterol: Implications in Cervical Cancer,” Cancer Investigation, Vol. 25, No. 3, 2007, pp. 172-181. doi:10.1080/07357900701209053
[48] H. Ohori, H. Yamakoshi, M. Tomizawa, M. Shibuya, Y. Kakudo, A. Takahashi, S. Takahashi, S. Kato, T. Suzuki, C. Ishioka, Y. Iwabuchi and H. Shibata, “Synthesis and Biological Analysis of New Curcumin Analogues Bearing an Enhanced Potential for the Medicinal Treatment of Cancer,” Molecular Cancer Therapeutics, Vol. 5, 2006, pp. 2563-2571. doi:10.1158/1535-7163.MCT-06-0174
[49] C. Karikar, A. Maitra, S. Bisht, G. Feldmann, S. Soni and R. Ravi, “Polymeric Nanoparticle-Encapsulated Curcumin (‘Nanoparticulate Curcumin’): A Novel Strategy for Human Cancer Therapy,” Journal of Nanobiotechnology, Vol. 5, 2007, p. 3. doi:10.1186/1477-3155-5-3
[50] W. Tiyaboonchai, W. Tungpradit and P. Plianbangchang, “Formulationand Characterization of Curcuminoids Loaded Solid Lipid Nanoparticles,” International Journal of Pharmaceutics, Vol. 337, No. 1-2, 2007, pp. 299-306. doi:10.1016/j.ijpharm.2006.12.043
[51] U. K. Parashar, P. S. Saxena and A. Srivastava, “Role of Na-nomaterials in Biotechnology,” Digest Journal of Nanomaterials and Biostructures, Vol. 3, No. 2, 2008, pp. 81-87.
[52] R. Ravichandran, “Nanoparticles in Drug Delivery: Potential Green Nanobiomedicine Applications,” International Journal of Green Nanotechnology: Biomedicine, Vol. 1, No. 2, 2009, pp. B108-B130.
[53] R. Ravichandran, “Nanotechnology-Based Drug Delivery Systems,” NanoBiotechnology, Vol. 5, No. 1, 2010, pp. 17-33. doi:10.1007/s12030-009-9028-2
[54] M. Sun, X. Su, B. Ding, X. L. He, X. J. Liu, A. H. Yu, H. X. Lou and G. X. Zhai, “Advances in Nanotechnology-Based Delivery Systems for Curcumin,” Nanomedicine, Vol. 7, No. 7, 2012, pp. 1085-1100. doi:10.2217/nnm.12.80